ATE194169T1 - Beta-type ähnlicher transformierender wachstumfaktor - Google Patents

Beta-type ähnlicher transformierender wachstumfaktor

Info

Publication number
ATE194169T1
ATE194169T1 AT92900433T AT92900433T ATE194169T1 AT E194169 T1 ATE194169 T1 AT E194169T1 AT 92900433 T AT92900433 T AT 92900433T AT 92900433 T AT92900433 T AT 92900433T AT E194169 T1 ATE194169 T1 AT E194169T1
Authority
AT
Austria
Prior art keywords
beta
tgf
protein
growth factor
transforming growth
Prior art date
Application number
AT92900433T
Other languages
English (en)
Inventor
Yasushi Owaga
David Schmidt
James Dasch
Original Assignee
Celtrix Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharma filed Critical Celtrix Pharma
Application granted granted Critical
Publication of ATE194169T1 publication Critical patent/ATE194169T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT92900433T 1990-11-16 1991-11-18 Beta-type ähnlicher transformierender wachstumfaktor ATE194169T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61430690A 1990-11-16 1990-11-16
PCT/US1991/008606 WO1992008480A1 (en) 1990-11-16 1991-11-18 A β-TYPE TRANSFORMING GROWTH FACTOR

Publications (1)

Publication Number Publication Date
ATE194169T1 true ATE194169T1 (de) 2000-07-15

Family

ID=24460682

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92900433T ATE194169T1 (de) 1990-11-16 1991-11-18 Beta-type ähnlicher transformierender wachstumfaktor

Country Status (9)

Country Link
US (1) US5462925A (de)
EP (1) EP0557418B1 (de)
JP (1) JPH06505965A (de)
AT (1) ATE194169T1 (de)
AU (1) AU660635B2 (de)
CA (1) CA2096441A1 (de)
DE (1) DE69132275T2 (de)
ES (1) ES2149167T3 (de)
WO (1) WO1992008480A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN271295A0 (en) * 1995-05-02 1995-05-25 Gropep Pty Ltd Method of treatment
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
US6194376B1 (en) * 1991-03-11 2001-02-27 Creative Biomolecules, Inc. Method for modulating inflammatory response comprising administering morphogen
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5847007A (en) * 1993-05-13 1998-12-08 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
AU5405494A (en) * 1992-10-30 1994-05-24 Genentech Inc. Method for preventing or treating liver disease
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE69637316T2 (de) * 1995-06-07 2008-08-28 Poniard Pharmaceuticals, Inc., Seattle Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen
CA2223595C (en) * 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
EP0894004B2 (de) 1996-03-22 2007-02-21 Curis, Inc. Verfahren zur verbesserten funktionelle erholung der motorische koordiination, der sprache oder der sinneswahrnehmung nach trauma oder isch?mie des zns
US6117911A (en) 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6846906B1 (en) * 1998-10-07 2005-01-25 Stryker Corporation Modified proteins of the TGF-β superfamily, including morphogenic proteins
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US7378432B2 (en) * 2001-09-14 2008-05-27 Tel Aviv University Future Technology Development L.P. Glycogen synthase kinase-3 inhibitors
CA2525647A1 (en) 2003-05-16 2005-02-24 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
WO2005032578A1 (en) 2003-10-06 2005-04-14 Monash University Therapeutic method
EP1740615B1 (de) 2004-03-31 2014-11-05 Genentech, Inc. Humanisierte anti-tgf-beta-antikörper
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP3265096B9 (de) * 2015-03-05 2023-10-04 TheiaNova Limited Ophthalmische zusammensetzungen und verfahren zur verwendung davon
AU2017268234A1 (en) 2016-05-17 2018-12-13 Genentech, Inc. Stromal gene signatures for diagnosis and use in immunotherapy
TW201923089A (zh) 2017-11-06 2019-06-16 美商建南德克公司 癌症之診斷及治療方法
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
EP4599088A1 (de) 2022-10-05 2025-08-13 Genentech, Inc. Verfahren und zusammensetzungen zur klassifizierung und behandlung von lungenkrebs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5115625A (en) * 1974-07-26 1976-02-07 Hokko Chem Ind Co Shushishodokuzai
JPS5333738U (de) * 1976-08-31 1978-03-24
JPS58121932A (ja) * 1982-01-12 1983-07-20 太田　孝治 チユ−ブ搾り装置
DE3382562D1 (de) * 1982-09-24 1992-06-25 Us Health Wiederherstellung von gewebe bei tieren.
JPS6034997A (ja) * 1983-05-09 1985-02-22 ジヨージ、ジヨセフ、トダロ 生物学的活性ポリペプチド類
US4843063A (en) * 1984-07-16 1989-06-27 Collagen Corporation Polypeptide cartilage-inducing factors found in bone
US4886747A (en) * 1985-03-22 1989-12-12 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
US4806523A (en) * 1985-08-06 1989-02-21 Collagen Corporation Method of treating inflammation
US4931548A (en) * 1987-01-30 1990-06-05 Techne Corporation Heterodimer form of transforming growth factor-beta
AU4056089A (en) * 1988-07-20 1990-02-19 Amgen, Inc. Method of treating inflammatory disorders by reducing phagocyte activation

Also Published As

Publication number Publication date
EP0557418A4 (en) 1994-09-14
AU660635B2 (en) 1995-07-06
WO1992008480A1 (en) 1992-05-29
EP0557418B1 (de) 2000-06-28
EP0557418A1 (de) 1993-09-01
DE69132275T2 (de) 2001-01-25
US5462925A (en) 1995-10-31
JPH06505965A (ja) 1994-07-07
ES2149167T3 (es) 2000-11-01
CA2096441A1 (en) 1992-05-17
AU9046791A (en) 1992-06-11
DE69132275D1 (de) 2000-08-03

Similar Documents

Publication Publication Date Title
ATE194169T1 (de) Beta-type ähnlicher transformierender wachstumfaktor
DE69129803D1 (de) Wasserlösliche peptidanaloguen mit bindungstellen
NZ330897A (en) Human trk receptors and neurotropic factor inhibitors
AU563962B2 (en) Cysteine depleted muteins of biologically active proteins
ES2147558T3 (es) Nuevos polipeptidos para promover la fijacion celular.
DE69016655D1 (de) Biologisch aktive polypeptide, die auf transformierten wachstumsfaktor-beta-sequenzen basieren.
ATE120374T1 (de) Markierte polypeptidderivate.
EE200100223A (et) Interferoon-beetaga sulandatud valgud ja nende kasutamine
ATE80166T1 (de) Verfahren zur isolierung rekombinanter polypeptide in biologisch aktiver form.
DE69129865D1 (de) Osteogene peptide
EP0330506A3 (de) VLA-Proteine
PT731811E (pt) Chaperonina 10
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
DE69528531D1 (de) D-2-alkyltryptophan enthaltende polypeptide mit wachstumhormon freisetzender aktivitaet
EP0725081A4 (de) MONOKLONALER ANTIKÖRPER GEGEN MxA DES MENSCHLICHEN Mx PROTEINS
CA2010256A1 (en) Protein anti-cancer agent
ES2168282T3 (es) D-hidantoinasa recombinante, procedimiento para su preparacion y utilizacion.
ATE110390T1 (de) Wachstumsfaktor-rezeptor.
DK0467839T3 (da) In-vitro-behandling af fusionsproteiner
EA200001252A1 (ru) КОМПОЗИЦИЯ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА-β-1A(IFN-β-1A) ЧЕЛОВЕКА
ES2159536T3 (es) Proteina que inhibe el crecimiento celular.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties